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ABSTRACT
The Mixed Lineage Leukemia (MLL) protein is a large, multi-domain protein that
serves as a positive regulator of gene expression during hematopoietic and embryonic
development. The MLL gene is associated with chromosomal translocations, which
produce MLL fusion proteins that can lead to the onset of myeloid, lymphoid, and mixedlineage leukemias. Each fusion protein retains the MLL amino-(N-)terminus; within this
portion of MLL is the repression domain. A recent yeast two-hybrid screening
experiment initiated by our laboratory, which used the repression domain of MLL as bait,
yielded nine positive clones of the Nipped B-like (NIPBL) protein.
NIPBL is a crucial member of the cohesin-loading complex. The cohesin
complex functions in the segregation of sister chromatids during mitosis and meiosis.
However, more recent evidence suggests the cohesin complex machinery can function as
a transcriptional regulator through enhancer-promoter looping of genes. An interaction
between the MLL repression domain and NIPBL could contribute additional insight on
MLL-dependent gene regulation in cells with wild type MLL and in MLL leukemias.
In the present study, we want to confirm this interaction using an independent
system. To validate the interaction of NIPBL with the MLL repression domain, GST
pull-down assays will be used. Because the NIPBL protein is quite large and is difficult
to express, subclones expressing smaller regions were created. NIPBL was divided into

viii

seven distinct regions based on sequence and previous functional information. All seven
regions were amplified using PCR and subcloned into an expression vector. Expression
of the subcloned domains and full length NIPBL in HEK 293T cells was shown at the
protein level through western blotting analysis. To confirm the interaction of NIPBL
with the repression domain of MLL, GST-tagged MLL repression domain protein was
expressed to perform GST pull-downs with the each of the NIPBL subclones. The results
of this project have shown and confirmed that NIPBL interacts, through amino acids 450637, with the repression domain of MLL.
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CHAPTER ONE
LITERATURE REVIEW
M ixed L ineage L eukemia
The Mixed Lineage Leukemia ( MLL ) gene is located on chromosome 11, band
q23 and was first identified due to its involvement in chromosomal translocations that
can lead to acute myeloid leukemia (AML), acute lymphoid leukemia (ALL) or those
with a mixed-lineage phenotype1. The chromosomal rearrangements generated cause an
in-frame fusion between MLL and over 60 different fusion partners (Figure 1)2. In all
translocations, the amino-terminus of MLL is fused in frame to a partner gene. This
results in the formation of a chimeric protein. The leukemias that are caused by the
translocations of the MLL gene account for 5-10% of all human acute leukemias3. They
are the predominant type of leukemia in infants as well as in patients who develop
leukemia after treatment with drugs targeted to DNA topoisomerase II1,4. In comparison
with other leukemias, the MLL leukemias are often more aggressive and have a worse
prognosis5,6.
Wild type MLL belongs to the Trithorax (trx) group of proteins based on
functional properties. These proteins are crucially involved in the positive regulation of
the homeobox (HOX) genes during embryonic and hematopoietic development7. Several
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key domains are conserved between MLL and the Drosophila trx protein. MLL is a
large, multi-domain protein (432 kD) that is present within the nucleus7. The wild type
MLL protein contains several functional domains within the carboxyl terminus of the
protein. Included in this region are the plant homeodomain (PHD) fingers and the SET
domain, both of which are conserved with trx. The PHD fingers function in proteinprotein interactions, including with post-translationally modified histone 3 (H3) tail7.
The SET domain has enzymatic histone methyltransferase activity, which is responsible
for trimethylation of H3K48,9. However, when the chromosomal rearrangements cause
the generation of MLL fusion proteins, only the N-terminal regions of MLL remain
intact. Within the N-terminus are the AT-hooks, which bind to AT-rich, nucleosomal,
and bent DNA. Also within this region is the repression domain (RD)10.
The repression domain, initially coined for its ability to repress transcription of
certain genes, is now associated with transcription activation and repression as well as
protein-protein interactions10. The repression domain has been shown to interact with
histone deacetylases (HDAC1) and other co-repressor proteins, including CtBP and
polycomb proteins HPC2 and BMI111. Within the repression domain is a CXXC domain
that binds to non-methylated CpG DNA sequences. The domain is named for the
conserved cysteine residues within the region; eight cysteine residues coordinate two zinc
atoms. The CXXC domain structure determines specific non-methyl-CpG DNA binding
activity through electrostatic and hydrogen bonding interactions12. The CXXC domain
and its DNA-binding ability have been shown to be essential for MLL translocations to
generate acute leukemias12,13. The repression domain is present in both wild type and
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F igure 1: M ixed L ineage L eukemia

Wild type MLL and an MLL fusion protein produced after chromosomal translocation.
Wild type MLL contains various regions including: AT hooks (DNA binding), nuclear
localization sequences (transport), repression domain (DNA and protein interactions),
PHD fingers (protein-protein interactions), and SET domain (enzymatic histone
methyltransferase). The MLL fusion protein retains some critical functional regions,
including the repression domain.
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MLL fusion proteins (Figure 1), thus understanding the function of this domain would be
relevant to both normal and aberrant MLL proteins.
The CXXC domain of MLL (MLL1) is homologous to the CXXC domains of
both MLL2 (MLL4) and DNMT1. The MLL2 protein, much like MLL, contains AThooks, PHD fingers, and CXXC and SET domains14. The presence of these similar
functional domains and amino acid sequence of these two proteins would suggest they
have similar enzymatic and regulatory functions within the cell. However, through
domain swapping of the MLL2 CXXC domain within the MLL CXXC of a MLL fusion
protein, the protein is unable to immortalize bone marrow progenitor cell15,16. DNMT1
CXXC domain, though, is able to confer transforming ability when swapped into a MLL
fusion protein17.
These studies have illustrated that the CXXC domain and the larger repression
domain of MLL are important regions in the normal and leukemia-causing functions of
MLL. There may be additional critical functional protein-protein interactions with MLL
that have yet to be determined. The repression domain is essential to in the function of
wild type and MLL fusion proteins and should be studied further11.
Y east T wo-H ybrid Screening for Protein-Protein Interactions
The interactions between proteins are vital to a cell. Cellular processes including
cell adhesion, transcription and translation, and antigen recognition are dependent on
protein-protein interactions. The yeast two-hybrid screen is one molecular and
biochemical technique that has been used to study these protein-protein interactions18.
The basis behind the screen is the functions of transcription factors of yeast.
Transcription factor DNA binding and activation domains can be expressed separately,
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and when they are brought together in the yeast cell through protein-protein interaction,
can generate a signal through activated gene expression. This idea has been modified
into an unbiased technique to identify novel protein-protein interactions. However, yeast
two-hybrid screens have yet to differentiate between a direct or indirect interaction
between the two resulting proteins.
While several variations of the yeast two-hybrid screen exist, all are designed to
allow for the successful identifications of protein interactions. The simplest of examples
utilizes the yeast Gal4 transcriptional activator19. Gal4 contains both a DNA-binding
domain and a transcriptional activation domain. Both domains can exist as separate
proteins, but must still be in proximity to allow for expression of the genes necessary for
survival of the yeast cells. This model allows for the generation of chimeric proteins
bound to either of the two domains within yeast cells that are starved of nutrients. If the
two proteins of interest interact with one another, then the Gal4 domains will be in close
enough proximity to allow for transcription of target genes to allow for survival under
specific experimental conditions18. The expression of the required genes acts as the
reporting mechanism for the yeast two-hybrid screen since only the cells with an
interaction will survive.
This experimental system has been modified over thirty years to improve
specificity. LexA and Tet-R modifications allow for stricter selection of positive
interactions. cDNA libraries have been created to scan through large numbers of proteins
in a single screening20,21. The yeast two-hybrid is quite a powerful tool, but caveats of the
technique must be taken into consideration. The screen identifies novel interactions
between two proteins within a yeast cell in an impartial selection process. However, to
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properly identify the interaction as bona fide, it must be re-confirmed in a different
system through another independent method.
Our laboratory recently initiated a yeast two-hybrid screen that used the
repression domain of MLL as bait. The screen yielded positive-interacting results for two
different proteins: NIPBL (nine clones) and the ribosomal protein S18 (RPS18) (one
clone).
Cohesin Complex
The cohesin complex is an integral group of proteins that allow for proper cell
functioning and survival22. Cohesin interacts with chromosomal and naked DNA. Four
proteins make up the cohesin machinery²the structural maintenance of chromosomes
(SMC) proteins 1 and 3 (Smc1 and Smc3), Rad21, and Stag223. The basis of the cohesin
complex functioning is the ATPase activity of Smc1 and Smc3. The ATPase regions of
Smc1 and Smc3 are located in the head domains of each protein. The SMC proteins form
a ring-like structure around DNA through a bridged interaction with Rad21. Stag2
interacts with the carboxyl-terminus of Rad21 within the protein complex (Figure 2;
center)24,25.
In addition to the four core proteins, two additional proteins are crucial for
function of the complex. Nipped B-like (NIPBL) and Mau2 form a separate heterodimer
that interact with both DNA and the Smc complex (Figure 2; center). Nipped B-like is
the ortholog of Drosophila Nipped-B. Nipped-B facilitates the activation of Drosophila

cut and Ultrabithorax homeobox genes through the interactions of distant enhancer
regions35. Mau2 is a homolog of the C. elegans mau-2, which has been shown to have a
role in mitotic segregation31. This dimer of NIPBL and Mau2 are known as the cohesin-
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loading complex; they function to load the cohesion ring structure around DNA26.
Coupled together, the activated ATPase domains of the Smc proteins interact with the
NIPBL/Mau2-loading complex to allow for proper functioning of the complex27.
For many years it has been known that the cohesin complex functions in three
main processes within the cell (Figure 2; left panel). After DNA replication, sister
chromatids are attached to each other prior to their separation during mitosis and meiosis.
The cohesin complex allows for the cohesion of the sister chromatids. The complex also
facilitates the spindle attachment to the chromosomes as well as the segregation and
condensation of the chromosomes. Lastly, cohesin plays a role in DNA repair through
the recombination mechanism22,28.
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F igure 2: Cohesin Complex

The cohesin complex: Smc proteins 1 and 3, Rad21, and SA/Stag2. Cohesin executes
several canonical functions and has more recently been shown to be involved with
additional gene regulatory processes with the aid of its loading complex (NIPBL and
Mau2). Modified from Dorsett 2011.
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Nipped B-like
Cornelia de Lange syndrome (CdLS) is a rare heterogeneous developmental
disorder29. This multisystem congenital anomaly is characterized by patients that have a
variety of defects, including upper limb reduction, craniofacial dysmorphia, cardiac and
gastrointestinal abnormalities, mental retardation, and pre- and post-natal growth
delay30,31. The prevalence of CdLS is estimated between 1/10,000 and 1/50,000 births;
however, due to the variable types of abnormalities, this could be an underestimate. In
2004, the genetic basis of CdLS was discovered25,30. Mutations in three genes have been
reported to cause CdLS in humans32,33. Mutations in Smc1a and Smc3 genes account for
5% of the patients with CdLS. These two genes code for subunits of the cohesin
complex. However, approximately 60% of CdLS patients have mutations in the NIPBL
gene. The phenotype of the syndrome is often dependent on which gene is mutated²
patients with Smc1a/3 mutations have mild structural problems with severe mental
retardation, while patients NIPBL mutations have severe organ and limb dysmorphia with
mild cognitive effects31,34.
Since the genetic foundation of CdLS was uncovered, NIPBL has been the focus
of many studies. The Nipped B-like (NIPBL ) gene codes for the NIPBL protein, which is
an ortholog of the Drosophila Nipped B, identified as a transcription factor, and yeast
Scc2, a component of the cohesin complex25. Much like in yeast, human NIPBL protein
was shown to be an active member of the cohesin complex that regulates processes
involving sister chromatids35. The NIPBL protein is one half of the cohesin-loading
complex along with Mau2 (Figure 2; center). NIPBL interacts with Mau2 and Rad21
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F igure 3: Schematic of Nipped B-like protein

Full-length Nipped B-like protein is 2804 residues and contains many domains. The
glutamine-rich region (418-462) as well as the domain (450-637) that was shown through
yeast two-hybrid screen to interact with MLL are located in the N-terminus. Seven,
NIPBL-specific PETPK amino acid repeats are located in residues 597-759. A
caldesmon domain was shown through NIPBL residues 489-1025. Also contained within
the protein are nuclear localization and export signals as well as PEST sequences, which
are important in proteosomal degradation. Located in the C-terminal portion of the
protein are five, HEAT domain repeats, which are important in protein-protein
interactions. Modified from Wierzba et al 2006.
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within the cohesin complex to allow for the Smc proteins to encircle chromosomal
DNA25,36.
The NIPBL protein is approximately 2800 amino acids in length. The threedimensional structure has yet to be solved; however, several specific sequences and
domains have been identified (Figure 3)29. Beginning with the amino-terminus, NIPBL
contains a glutamine (Gln)-rich region (aa 418-462), which has fourteen Gln residues in
that stretch. Glutamine repeats have been shown to be integral in protein-protein
interactions between co-activators. Also within the N-terminus is the domain (residues
450-637) that was identified through the yeast two-hybrid screen to interact with the
repression domain of MLL. A previously shown caldesmon domain, which is important
in binding interactions with calmodulin and actin proteins, is located in residues 4891025. Residues 597-759 include seven NIPBL-specific amino acid repeats with the
sequence PETPK. No function has yet been assigned to these repeats. NIPBL also
includes bipartite nuclear localization and export signals. In addition, the protein
contains five HEAT-domain repeats near the carboxyl-terminus of the protein37. These
HEAT domains also function in protein-protein interactions38. Two PEST sequences,
which are important in proteosomal degradation of proteins, are found in at residues
1149-1170 and 2627-2646. Through the analyses of CdLS patients, mutations have also
been identified that span most of the NIPBL protein29.
CdLS is caused by heterozygous loss-of-function mutations of NIPBL. The
mutations reduce expression of NIPBL by approximately 30%, and a 15% decrease in
expression is sufficient to cause CdLS37. The diminished amount of NIPBL does not
cause any effects on the cohesin complex or chromosomal segregation during mitosis and
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meiosis38. However, the gene expression profiles of heterozygous mutant Drosophila,
yeast, mouse, and humans all show changes. The lack of effects on mitotic functions of
the cohesin complex with the NIPBL mutations argues that CdLS is caused by a different
mechanism²perhaps changes in gene expression25.
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F igure 4: G ene Regulation Mechanisms of Cohesin and N IPB L
A

B

The two proposed mechanisms of gene regulation by cohesin and Nipped B-like. A)
Cohesin complex interacts with CCCTC-binding factor (CTCF) leading to looping and
sequestering of enhancer region from promoter, which causes inhibition of the target
gene expression. B) Cohesin and NIPBL loop the enhancer towards the transcriptional
start site where they can interact with RNA polymerase and the Mediator (a large, multisubunit transcriptional activator) complex to lead to increased gene expression. Modified
from Dorsett 2011.
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Recent experiments support a model whereby NIPBL and cohesin act to regulate
gene expression through the looping of DNA (Figure 2; right panel)25. Two hypothetical
modes have been proposed for the effect of NIPBL and cohesin on gene regulation
because experiments have shown both increased and decreased gene expression due to
these proteins. The inhibitory mechanism has been shown to occur at several genes
(Figure 4A). Through gene expression analysis and the technique Chromosome
Conformation Capture (3C), the NIPBL-dependent cohesin complex has been shown to
mediate DNA looping at the homeobox gene A locus and at the ß-globin locus39,40. At
both loci, NIPBL and cohesin interact with the CCCTC-binding factor (CTCF; Figure
4A) at insulating elements to cause the inhibition of expression.
As for the activating mechanism, in a recent study, cohesin, Nipped B-like, and
the mediator complex were shown to mediate DNA looping at genes with positive
changes in expression41. Again, 3C was used to determine looping between enhancer and
promoter regions of Nanog, Phc1, Oct4, and Lefty1 genes. These genes are expressed in
embryonic stem (ES) cells, but not in mouse embryonic fibroblasts (MEFs). It was
shown that there is an increased frequency of looping between enhancer and promoter
regions in ES cells over MEFs. Also, ChIP-seq was used to show that cohesin, mediator
and Nipped B-like occupy the enhancer and promoter regions as well41. Other such
studies have shown positive regulation of other genes (c-Myc) by a Nipped B-likedependent cohesin complex42. Put together, these studies form the basis of a hypothetical
mechanism through which the cohesin complex acts with the Mediator complex, a large,
multi-subunit protein transcriptional regulator, and RNA polymerase to regulate gene
expression through a DNA looping mechanism (Figure 4B).

CHAPTER TWO
METHODS
Y east T wo-H ybrid Screen
The repression domain of MLL (amino acids 1101-1433; sequence from NCBI
L04284) was sent as bait for a yeast two-hybrid screening project to identify possible
interactions with other proteins. The yeast two-hybrid screen was performed by
ProteinLinks, Inc. (Pasadena, CA; www.proteinlinks.com). The screening was run
against a human fetal brain library using the TetR yeast two-hybrid approach. A total of
2.6x106 cDNA clones were screened with the bait MLL resulting in 10 verified
interacting clones.
V erification of full length Nipped B-L ike
From the results of the yeast two-hybrid screen, the Nipped B-like protein
(NIPBL) was a viable target to pursue. pFLAG-N3 NIPBL and pEGFP-N3 NIPBL
plasmids were obtained from Frank J. Kaiser, PhD (University of Lubeck, Lubeck,
Germany)22. The Kaiser lab had assembled full length NIPBL cDNA sequence and
cloned it into these two different plasmids, but had not attempted western blot to
determine protein expression (Kaiser, unpublished data). The plasmid DNA from each
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construct was electroporated into DH5Į electrocompetent cells using 1 µL (125 ng) of
the plasmid DNA and 20 µL bacterial cells using the following electroporator settings: 4
NȍUHVLVWDQFH)FDSDFLWDQFH (Cell-Porator; Life Technologies, Inc.). The
transformants were miniprepped using the GeneJET Plasmid Miniprep Kit (Fermentas,
Catalog #K0503). The miniprepped plasmid DNA from each construct was digested with
the restriction enzyme BamHI (New England BioLabs, Catalog #R0136) to linearize the
plasmid DNA. The reactions included 5 µL ddH2O, 1 µL (200 units) BamHI, 1 µL
BamHI buffer, and 3 µL (375 ng) plasmid DNA and were incubated at 37°C for 2 hours.
The resulting digested DNA was electrophoresed on a 1% agarose gel and compared with
uncut control plasmid DNA to confirm the linearization of each plasmid.
C loning of Nipped B-like Subdomains
In order to generate clones of the subdomains (Table 1) of Nipped B-like
(NM_015384.4), the following PCR reaction was set up for each subclone: 31 µL
ddH2O, 10 µL 5X HF buffer, 5 µL dNTPs, 1 µL (125 ng) pFLAG-N3 NIPBL plasmid
DNA, 1.25 µL (2 ng) Forward Primer (Table 2; Integrated DNA Technologies), 1.25 µL
(2 ng) Reverse Primer (Table 2; Integrated DNA Technologies), 0.5 µL (2 units) Phusion
DNA Polymerase (New England BioLabs, Catalog #M0530). Additional non-NIPBL
sequence was added to the PCR primers to facilitate in-frame cloning in the vector (Table
2). The PCR reactions were run in the PCR Express Thermal Cycler (Hybaid) according
to the following settings: one cycle of 95°C for 2 minutes; 40 cycles of 95°C for 45
seconds, 55°C for 45 seconds, 72°C for 2.5 minutes; and 1 cycle of 72°C for 10 minutes
with a holding temperature of 4°C.
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T able 1: Nipped B-like subcloned coding regions and specifications
Subclone Region
(amino acid #)

Nucleotide Sequence
(nucleotide #)

Restriction E nzyme
Sites

Total A mino A cid

1-450

500-1850

SalI, BamHI

450

Estimated
Size
(kd)
49

418-462

1754-1886

EcoRI, BamHI

44

5

450-637

1850-2411

EcoRI, BamHI

187

20

590-800

2270-2900

EcoRI, BamHI

210

24

800-1700

2900-5600

EcoRI, BamHI

900

101

1700-2400

5600-7700

EcoRV, BamHI

700

80

2400-2597

7700-8291

EcoRI, BamHI

197

22

The amplified DNA was cleaned using the QIAEX II PCR Clean-Up Kit
IROORZLQJWKHPDQXIDFWXUHU¶VVXJJHVWHGSURWRFRO 4LDJHQ&DWDORJ 7KHLQVHUW
fragment DNA was digested with a specific set of two restriction enzymes (Table 1; SalI,
60 units, New England BioLabs, Catalog #R0138; EcoRI, 60 units, New England
Biolabs, Catalog #R0101; EcoRV, 45 units, New England BioLabs, Catalog #R0195).
The reactions involving EcoRI/BamHI and EcoRV/BamHI restriction enzymes were
simultaneously incubated at 37°C for 2 hours. The SalI/BamHI combination was
sequentially digested²SalI digestion occurred the night before. The following morning
an additional 20 units of SalI was added with BamHI to the reaction mixture. Each insert
fragment was then electrophoresed and subsequently cut from a 1% agarose gel. The
DNA was purified using the QIAEX II Gel Extraction Kit (Qiagen, Catalog #20051),
DFFRUGLQJWRWKHPDQXIDFWXUHU¶VSURWRFRO7KHLQVHUW'1$ZDVVWRUHGDW-20°C until
further use.
The expression vector that the subcloned regions would be inserted into is
pFLAG-CMV2 to generate FLAG-tagged proteins. To allow for the subcloned
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constructs to be properly inserted into the vector, pFLAG-CMV2, was digested with the
identical combinations of restriction enzymes as the matching inserts. The resulting
digested vector was gel extracted using the QIAEX II Gel Extraction Kit.
The gel extracted inserts and vector were then ligated together under the
following protocol: 5 µL (1.5 µg) DNA, 1 µL (0.5 µg) vector, 1.5 µL 10X T4 Buffer, 1
µL (400 units) T4 DNA Ligase (New England Biolabs, Catalog #M0202L), and 7.5 µL
ddH2O. The reactions were left in a 16°C water bath overnight. The ligations were
electroporated into DH5Į electrocompetent cells using 1 µL DNA and 20 µL bacterial
cells. The transformants were plated and selected on LB/ampicillin plates. The selected
colonies were miniprepped using the GeneJET Plasmind Miniprep Kit. The plasmid
DNA from each subclone was sent for sequencing at ACGT, Inc (Wheeling, IL). The
resulting sequences were verified using NCBI Blast. Once verified, the correct clones
were midiprepped (Qiagen Plasmid Midi Kit, Catalog #12145) and the resulting DNA
was saved for future use.
T able 2: Primers for amplifying N IPB L subdomain regions for cloning
A mplicon
NIPBL 1-450
NIPBL 418-462
NIPBL 450-637
NIPBL 590-800
NIPBL 800-1700
NIPBL 1700-2400
NIPBL 2400-2597

Primer Sets
)RUZDUG1,36DO)¶aaagcgG T C G A C $7*$$7****$7$7*¶
5HYHUVH1,3%DP5¶cgG G A T C CTCA&$&$*$$*7&7***¶
)RUZDUG1,35,)¶aaG A A T T CT&$$7*777*7&*&$*&¶
5HYHUVH1,3%DP5¶cgG G A T C CTCACTGT7*7*$7$7&7*¶
)RUZDUG1,35,)¶aaG A A T T CT*7**7$&$*$$7&$$&¶
5HYHUVH1,3%DP5¶cgG G A T C CTCA77&$&77*$7777*7&7&&¶
Forward: 1,35,)¶DDG A A T T CT$$$7&7$&$&&$*$$$$&&¶
5HYHUVH1,3%DP5¶cgG G A T C CTCA**&77&$*&7&*77&¶
)RUZDUG1,35,)¶aaG A A T T CA*&&77$$$*&$*$*¶
5HYHUVH1,3%DP5¶cgG G A T C CTCA$*$7*$77&77&$7&¶
)RUZDUG1,359)¶aaG A T A T CA7&7*$$**$$&$&$7&¶
5HYHUVH1,3%DP5¶cgG G A T C CTCA7&&$&**$7&$7*¶
)RUZDUG1,35,)¶aaG A A T T CT**$$$&&*&&$$&¶
5HYHUVH1,3%DP5¶cgG G A T C CTCA&$**$$*7&&$*7*¶

In the above table, restriction enzyme sites are displayed as bolded text. The stop codons
are highlighted in red, and the additional non-Nipped B-like bases of the oligos are
lowercased. The plain, capitalized text is the coding sequence of Nipped B-like.
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C ell C ulture
All cell culture work was performed using the Human embryonic kidney cell line,
HEK 293T. The HEK 293T cells were cultured in DMEM (HyClone), 10% FBS, 1%
penicillin/streptomycin in a 37°C incubator with 5% carbon dioxide.
For the transfections of subclones, 2.4x106 HEK 293T cells were plated on 10cm
plates with 10 mL of culture media. Each plate was transfected 24 hours later with 25 µg
of plasmid DNA (pFLAG-CMV2 NIPBL, all seven subclones, pcDNA HDAC1 FLAG
positive control, and untransfected HEK 293T negative control). The CalPhos
Mammalian Transfection Kit (Clontech, Catalog #631312) was used for the transfections.
Fresh media was added 24 hours post-transfection. After 48 hours post-transfection, the
cells were counted and stored in 1.5mL microcentrifuge tubes at a concentration of 5x106
cells per tube. The cell pellets were snap-frozen and stored at -80°C.
Protein E xtraction
The 5x106 cell aliquots were thawed on ice and combined with 500 µL cold IPH
buffer (50 nM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 1:100
Protease Inhibitor cocktail (Sigma, Catalog #P8340)) by gentling pipetting the mixture in
a 1.5 mL microcentrifuge tube. The cells were incubated on ice for 10 minutes. The
tubes were centrifuged at maximum speed (14,000 rpm) for 30 minutes at 4°C. The
supernatant, which contained the expressed protein constructs, was removed and snapfrozen in 450 µL and 50 µL aliquots. The aliquots of FLAG-tagged proteins were stored
at -80°C for future use.
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W estern Blot A nalysis
SDS-polyacrylamide gels with 12%-resolving (4.4 mL ddH2O, 3.0 mL 40%
acrylamide, 2.5 mL Tris pH 8.8, 0.1 mL 10% SDS, 50 µL 10% APS, 10 µL TEMED) and
4%-stacking (7.68 mL ddH2O, 0.975 mL 40% acrylamide, 1.25 mL Tris pH 6.8, 0.1 mL
10% SDS, 50 µL 10% APS, 10 µL TEMED) were poured with 10-well combs. The 50
µL protein samples were prepared by adding 10 µL of 6X SDS loading buffer (2.5 mL
1M Tris pH 6.8, 1 g SDS, 0.05 g Bromophenol Blue, 5 mL glycerol, 2.5 mL ddH2O, 500
mM DTT). The samples were boiled at 95°C for 5 minutes and then loaded into the
SDS-PAGE gels. Precision Plus Protein Kaleidoscope Standard (10 µL; Bio-Rad,
Catalog #161-0375) was used as the MW ladder. The gels were placed in 1X Running
Buffer (15.1 g Tris base, 94 g Glycine, 50 mL 10% SDS, filled to 1 L with ddH2O) and
electrophoresed at 150 V for 1 hour.
Immobilon PVDF Transfer Membranes (Millipore, Catalog #IPVH00010) were
soaked in methanol for 10 seconds and then washed in ddH2O. The gels were transferred
to the membranes in the BioRad Electro-Eluter at 70 V for 2.5 hours using 1X Transfer
Buffer (2.42 g Tris base, 11.26 g Glycine, 100 mL methanol, fill to 1L with ddH2O).
Once transferred, the membranes were placed in 50 mL of blocking solution
(PBS-0.05% Tween with 5% milk w/v; (Jewel Instant Nonfat Dry Milk)) overnight in the
4°C cold room while on the rocker (Boekel Orbitron Rotator II). The membranes were
then incubated with primary antibody (Sigma-Aldrich Monoclonal anti-FLAG M2,
Catalog #080M6034, in 8 mL of blocking solution; 1:3000 dilution) at room temperature
for 2 hours in the glass rotator (AutoBlot, BellCo Glass, Inc.). Following the incubation,
the membranes were washed three times for 5 minutes each with 50 mL of PBS-Tween
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on the BellyDancer (Stovall Life Sciences, Inc.). The membranes were incubated with
secondary antibody (Amersham ECL anti-mouse IgG HRP, Catalog #NA931, in 8 mL of
blocking solution; 1:8000 dilution) for two hours at room temperature in the rotator. The
membranes were washed three times with 150 mL of PBS-Tween on the BellyDancer.
To develop the membranes, Pierce ECL Western Blot Substrate (Catalog #32106)
was added to the membranes. The solution was left on the membranes for 1 minute. The
excess ECL solution was drained, and the membranes were wrapped in plastic wrap. The
membranes were then placed in the x-ray film holder (Fisher Biotech Autoradiography
Cassette). An x-ray film sheet (Hyblot CL Autoradiography Film, Catalog #E3012) was
placed on the membrane in the dark room for 15 minutes. After that time duration, the
film was placed in the Alpha Tek Developer (Model #AX390 SE) and allowed to
develop. The film was marked for the prestained Kaleidoscope ladder following the
development. The membranes were peeled from the plastic wrap, placed in PBS-Tween,
and stored in the 4°C refrigerator for future blotting analyses.
Immunoprecipitation Assay
The anti-FLAG M2 beads (40 µL; Sigma-Aldrich anti-FLAG M2-agarose Catalog
#045K6065) were pre-blocked with 200 µL of Z-Buffer (25 mM HEPES, pH 7.5, 12.5
mM MgCl2, 150 mM KCl, 0.1% NP-40, 20% glycerol, final concentration 1 mg/mL
BSA, 1:10 Protease Inhibitor cocktail) and left to incubate for 15 minutes on ice. The
mixture was centrifuged at 1,500 rpm for 30 seconds. The supernatant was removed.
The 450 µL aliquots of FLAG-tagged proteins were thawed and added to the pre-blocked
anti-FLAG M2 beads. The mixture was placed on the circular rotator (Glas-Col) in the
cold room overnight.
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The following day, the mixture was centrifuged at 1,500 rpm for 30 seconds and
the supernatant was removed. The beads were then washed four times, each with 1 mL
of NETN Buffer (100 mM NaCl, 1 mM EDTA, 0.5% NP-40, 20 mM Tris-HCl, pH 8.0,
1:10 Protease Inhibitor cocktail). After the final removal of supernatant, the beads were
resuspended in 40 µL of 1X SDS loading buffer. The samples were boiled for 5 minutes
at 95°C and centrifuged at 1,500 rpm for 1 minute. The supernatant from each sample
was loaded into a 12%-resolving, 4%-stacking SDS-PAGE gel. The previously
mentioned western blotting protocol was used thereafter (see above).
Generation of GST fusion proteins
GST-fusion MLL repression domain (pGEX-KT MLL RD; glycerol stock #55)
and GST alone (pGEX-KT empty vector; glycerol stock #40) were streaked out on
LB/ampicillin plates and incubated at 37°C overnight. From the plates, a single colony
was picked and grown in 25 mL of LB media overnight. The cultures were then
expanded into 1 L of LB media for 4 hours. To induce protein production, 1 mL of 100
mM IPTG was added, and the cultures were allowed to grow for 3 more hours. The cells
were centrifuged at 5800 rpm for 15 minutes and then resuspended in 20 mL of Lysis
Buffer (500 mM Tris-HCl, pH 8.0, 300 mM NaCl, 1 mM EDTA, Protease Inhibitor
cocktail 1:1000, 30 mg Lysozyme, 3 mL Triton).
The cultures were incubated on ice for 5 min with frequent inversion. Following
the incubation, the cell lysates were sonicated twice for 20 seconds (setting 5). The
lysates were centrifuged at 9000 rpm for 30min at 4°C. GST beads (45 mg; SigmaAldrich, Catalog #G4510) were swelled the previous night in 10 mL ddH2O. The lysates
were combined with GST beads and incubated on the rotator at 4°C overnight. The
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following day, the beads were washed four times with 1 mL of Lysis Buffer. The beads
were resuspended in a 50% bead/volume ratio and stored at 4°C for future use.
To determine expression of the GST-fusion proteins, Coomassie staining was
used. The GST-fusion MLL repression domain (40 µL of 50% slurry) and GST-alone
(10 µL of 50% slurry) beads were centrifuged at 1,500 rpm for 30 seconds. The
supernatant was removed, and the beads were resuspended in 40 µL of 1X SDS loading
buffer. The samples were boiled for 5 minutes at 95°C and centrifuged at 1,500 rpm for
1 minute. The supernatant from each sample was loaded into a 10%-resolving, 4%stacking SDS-PAGE gel. The gel was placed in 1 L of 1X Running Buffer and
electrophoresed at 150 V for 1 hour.
After the gel was run, it was placed in a Tupperware container filled with 200 mL
of Coomassie Stain (0.25% Brilliant Blue, 45% methanol, 10% acetic acid, fill to 1 L
with ddH2O) and allowed to mix on the BellyDancer at room temperature for 2 hours.
Following the staining, the gels were placed in 200 mL of Destain (40% methanol, 10%
acetic acid, 50% ddH2O) overnight. The gels were vacuum-dried on the Bio-Rad Gel
Dryer (Model #583) to preserve the gel.
GST Pull-down Assay
The GST-fusion MLL repression domain (40 µL) and GST-alone beads (10 µL)
were pre-blocked with 200 µL of cold Z-Buffer and left to incubate for 15 minutes on ice.
The mixture was centrifuged at 1,500 rpm for 30 seconds. The supernatant was removed.
The 450 µL aliquots of FLAG-tagged proteins were thawed and added to either the preblocked GST MLL repression domain or GST-alone beads. The mixtures were placed on
the circular rotator in the cold room overnight.
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The following day, the mixture was centrifuged at 1,500 rpm for 30 seconds and
the supernatant was removed. The beads were then washed four times with 1 mL of cold
NETN Buffer. After the final removal of supernatant, the beads were resuspended in 40
µL of 1X SDS loading buffer. The samples were boiled for 5 minutes at 95°C and
centrifuged at 1,500 rpm for 1 minute. The supernatant from each sample was loaded
into a 12%-resolving, 4%-stacking SDS-PAGE gel. The previously mentioned western
blotting protocol was used thereafter (see above).

CHAPTER THREE
RESULTS
A im 1: C lone subdomain regions of Nipped B-like protein into
mammalian expression vector and verify expression of the
full-length and subdomain proteins
In a recent yeast two-hybrid screen, the MLL repression domain (amino acids
1101-1433) was used as bait to determine interactions with other proteins. Through the
screen, it was shown that the MLL repression domain interacts with a small region of
Nipped B-like protein (nine positive clones) and human ribosomal protein S18 (one
positive clone). Further studies to validate the interaction of MLL repression domain and
the Nipped B-like protein were pursued because of the high number of clones obtained
with the yeast two-hybrid system.
Nipped B-like, a homolog of Drosophila Nipped B, is part of the cohesin-loading
complex, which has been shown to be integral to the cellular processes of mitosis and
meiosis25. Recently, however, Nipped B-like and the cohesin complex have been shown
to have a role in the process of regulating gene expression. It was not until the genetic
basis for Cornelia de Lange syndrome (CdLS) was uncovered, that this non-canonical
function of cohesin and Nipped B-like was realized30-33. Examples of cohesion complex
proteins involved in the process of gene regulation have been shown in Drosophila, yeast,
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and mouse models25.
To confirm the interaction that was shown in the yeast two-hybrid screen, we
must first express Nipped B-like protein, which has yet to be done. Nipped B-like is a
very large protein (2804 amino acids), and is shown here to be expressed at a low level
(Aim 1B and Aim 2). However, we would like to show a direct interaction between the
full-length NIPBL protein and the repression domain of MLL. Thus, we decided to
subclone it into smaller fragments to facilitate expression for interaction studies. The
full-length protein was sub-divided into seven subclones for expression (Figure 5).
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F igure 5: Subclones of Nipped B-L ike

The full-length Nipped B-like (NIPBL) coding sequence as well as the seven subdomain
coding regions, which were subcloned into mammalian expression vector, pFLAG CMV2, in order to yield N-terminally tagged fusion proteins. The seven subdomain regions
were created based on previous sequence comparisons and protein analyses. Amino
acids (AA) 1-450 define the N-terminus of NIPBL. AA 418-462 contains the entire
glutamine-rich region. AA 450-637 contains the NIPBL region identified to interact with
the MLL repression domain by yeast two-hybrid screen. AA 590-800 contains the 7,
NIPBL-specific PETPK repeats. AA 800-1700 contains both nuclear localization and
export signals as well as a PEST sequence. AA 1700-2400 contains the HEAT domain
repeats and AA 2400-2597 is the C-terminus of NIPBL, which contains a PEST
sequence.
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Generate subclones of N IPB L according to sequence and
available functional information
A study published in 2006 analyzed mutations in the Nipped B-like gene in
Cornelia de Lange syndrome patients. The entire protein was also analyzed using webbased programs to identify functional domains and motifs. We therefore designed seven
subclones, which span the entire protein, keeping previously identified or suggested
domains intact (Figure 5)29. Table 1 (p. 17) depicts the specific nucleic acid bases and
amino acids that the subclones encompass. We had received both pFLAG-N3 NIPBL
and pEGFP-N3 NIPBL plasmid vectors from Frank J. Kaiser, Ph.D22. Dr. Kaiser had
assembled and sequenced the full-length NIPBL in these vectors. However, he had not
yet validated protein expression from these vectors. The NIPBL cDNA is approximately
8,300 base pairs. Upon enzymatic digestion of the two vectors with restriction enzyme
BamHI to release the NIPBL cDNA insert, the proper sized insert band was confirmed on
a 1% agarose gel (Figure 6).
DNA of full-length plasmid was then used as the template to PCR amplify the
subdomain regions. Using pFLAG-N3 NIPBL as the template, primer sets were designed
for each of the subclones (Table 2; p. 18). The subclones will be referred to based on
their amino acid sequence: NIPBL 1-450 (amino-terminus), NIPBL 418-462 (glutaminerich region), NIPBL 450-637 (region identified in yeast two-hybrid screen), NIPBL 590800 (PETPK repeats), NIPBL 800-1700 (NLS/NES), NIPBL 1700-2400 (HEAT repeats),
NIPBL 2400-2597 (carboxyl-terminus). As previously mentioned, the amino acid limits
of the subclones were designed based on sequence and structural data, however, NIPBL
2400-2597 was shortened from the end of the full-length protein because of a splice
variant that ends shortly thereafter.
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F igure 6: Confirmation of full-length Nipped B-like plasmids

Photo of the two different full-length NIPBL plasmid DNAs after undergoing restriction
enzyme digestion. Undigested plasmid DNA (uncut) is supercoiled and does not migrate
according to size. Restriction enzyme digestion (cut) linearized the plasmid DNA, which
causes the DNA to migrate according to its size after electrophoresis on a 1% agarose gel.
Both plasmids have an approximate length of 12kb. Approximate DNA sizes (base pairs)
are indicated on the 1kb ladder.
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Each of NIPBL subregions was PCR amplified as shown on a 1% agarose gel
(Figure 7). The subcloned regions were inserted into the pFLAG-CMV2 expression
vector. This would allow for the expression of FLAG-tagged proteins, so each
subdomain protein could be detected with the same antibody. Once the inserts were
ligated into the expression vector, the plasmid DNA was transformed into DH5Į bacterial
cells. After ampicillin selection of colonies, four individual colonies were selected per
construct to miniprep. The miniprepped supercoiled DNA from each subclone was
electrophoresed on a 1% agarose gel, and compared against uncut pFLAG-CMV2 vector
control. We analyzed the agarose gels by determining which clones had DNA which
migrated more slowly in the gel. A slower migrating DNA would correspond to a larger
plasmid containing an insert as opposed to the uncut, empty vector control. The clones
with slower migration as compared to the control, were chosen to send for DNA
sequencing using the pFLAG-CMV2 forward (CMV30) and reverse (CMV24) primers
(Integrated DNA Technologies). The plasmid DNA from these subclones was sent for
sequencing at ACGT, Inc. All of the sevHQFORQHV¶VHTXHQFHVZHUHYHULILHGXVLQJ1&%,
Blast to confirm the subclones did not have any mutations, started and ended at the
correct sequences, and inserted properly into the expression vector (Figures A5-11).
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F igure 7: PC R A mplified Nipped B-like subdomain coding regions

Photo of the PCR amplified NIPBL subdomain coding regions. NIPBL amplicons are
shown on the 1% agarose gel and denoted by the amino acid sequence they encode.
pFLAG-CMV2 expression vector DNAs are shown after being enzymatically digested by
the indicated pairs of restriction enzymes (B-BamHI, EI-EcoRI, EV-EcoRV, S-SalI).
Approximate DNA sizes (base pairs) are indicated.
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Confirm expression of full length and subcloned N IPB L regions
In our work with Nipped B-like, we have generated the seven subclones and
verified their DNA sequences. The subclones were inserted into the mammalian
expression vector, pFLAG-CMV2. In order to confirm the interaction of MLL repression
domain and Nipped B-like protein, we first had to determine whether protein was
expressed from the full-length NIPBL plasmid and the seven subclone plasmids.
Plasmid DNA was transfected into HEK 293T cells using the calcium phosphate
transfection technique. After 48 hours following the transfections, the cells were lysed
and the whole cell lysate from each construct was prepared. To determine expression of
each construct as well as the full-length protein, the whole cell lysates were
electrophoresed on SDS-PAGE gel and transferred to PVDF membrane. The pFLAGCMV2 vector allowed us to probe the blots with anti-FLAG M2 primary antibody to
view the expression of the respective proteins. The full-length NIPBL protein (predicted
316 kD) was observed after a long exposure time (Figure 8A; left panel). The expression
of the full-length, FLAG-tagged NIPBL was observed in one experiment.
Next, the seven subclones were expressed and western blot analysis was again
used to view their expression in HEK 293T cells. Proteins from four of the seven
subclones have only been observed in one experiment (Figure 8A). These are NIPBL 1450, NIPBL 418-462, NIPBL 1700-2400, and NIPBL 2400-2597. Proteins from the two
other subclones: NIPBL 450-637 and NIPBL 590-800 have been observed in multiple
western blots (Figure 8B; right panel). NIPBL 450-637 has been shown to be expressed
in over five separate experiments while NIPBL 590-800 was shown in four. As seen in
Figure 8B, NIPBL 450-637 (region matching yeast two-hybrid screen) has multiple
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bands. We believe the lowest band to be a degradation product within the cells, while the
two upper bands likely represent the protein and a modified version of the protein, which
would cause a super shift in the SDS-PAGE gel. Since this degradation product is
observed on immunoblot, it must have the N-terminal FLAG tag within the protein.
Thus, the lowest band of NIPBL 450-637 occurs towards the N-terminal portion of that
region.
To further determine whether there was any protein expression from the
remaining constructs, we chose to perform FLAG immunoprecipitations (IP). NIPBL
800-1700 was shown in two, separate FLAG-IP experiments to be expressed (Figure 8B;
left panel). The four subclones NIPBL 1-450, NIPBL 418-462, NIPBL 1700-2400, and
NIPBL 2400-2597 that were only shown to be expressed in one western blot have not
been successfully immunoprecipitated using the anti-FLAG M2 agarose beads to this
point. This could be due to multiple different reasons, including poor transfection
efficiency. Repeats of the IP experiments will be performed in future.
From the protein expression analysis, we can conclude that we can express the
full-length Nipped B-like protein as well as the seven subclones, however, optimized
expression and detection of some subclones needs to be further pursued.
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F igure 8: Protein E xpression analysis of Nipped B-like
A

B

Immunoblots of NIPBL protein regions using anti-FLAG M2. A) Western blot analysis
of full-length and subdomain regions of NIPBL. Control untransfected whole cell lysates
(WCL) from either HEK 293T or Phoenix-Eco (ĭNX) cells were used for comparison.
B) Left panel , FLAG-IP experiment of NIPBL 590-800 and NIPBL 800-1700. Proteins
are boxed in red; IgG heavy and light chains are noted. Right panel, western blot of
NIPBL 450-637 and NIPBL 590-800. Expressed proteins are boxed in red.
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A im 2: Determine whether the Nipped B-like protein interacts
with the M L L repression domain
Since yeast two-hybrid screening is often confounded with false positive results,
and it is performed in yeast cells, it was necessary to confirm the interaction between
Nipped B-like and the MLL repression domain in another system. Here, we use HEK
293T cells for expression of Nipped B-like protein and subclones. Based on the
information from the yeast two-hybrid screening, we predict Nipped B-like to interact
with the repression domain of MLL. In this aim, our goal is to confirm this novel
interaction through the biochemical technique, GST pull-down, and to determine which
region(s) of NIPBL can mediate this interaction.
Confirm the interaction of N IPB L and the M L L repression domain
GST pull-down assays were used to test the hypothesis that the interaction
between the repression domain of MLL and Nipped B-like protein was a bona fide
interaction in vitro. The Nipped B-like proteins were expressed in HEK 293T cells and
harvested as whole cell lysate. To perform the GST pull-down assay, we had to first
express the MLL repression domain. The MLL repression domain (1100-1400) inserted
into a GST expression vector was used to express a GST-tagged MLL RD, which could
bind to glutathione agarose beads for GST pull-down assays. E.coli transfected with
either pGEX-KT MLL RD (1100-1400) or pGEX-KT empty vector control were cultured
and expression of the proteins was induced by IPTG. After induction, the cells were
harvested and lysed. The GST proteins were enriched by incubating the cell lysates with
glutathione agarose beads, followed by several washes.
The GST-tagged MLL repression domain and GST-alone proteins were first
analyzed through Coomassie staining (Figure 9). The staining allowed for normalization
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of the amount of protein/beads added to the GST pull-down reactions. The proteins were
detected in four separate experiments.
We hypothesized that full-length Nipped B-like would interact with the repression
domain to support the evidence of the yeast two-hybrid results. However, due to the size
and low level of expression of the full-length Nipped B-like protein, we were unable to
show the interaction with the full-length protein. The GST pull-down of the full-length
NIPBL and GST MLL repression domain was tried once prior to continuing with the
subdomain proteins. Thus, to confirm the interaction with MLL and to determine
whether additional regions of the protein can contribute to binding, we will be looking at
the individual subclones.
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F igure 9: Coomassie staining of GST fusion proteins

Coomassie staining of the GST fusion proteins. The MLL repression domain (MLL RD)
was generated as a GST fusion protein from pGEX-KT MLL RD (1100-1400). GST
alone was generated from empty pGEX-KT vector. The proteins were bound to
glutathione beads, washed, and then incubated with SDS loading buffer before
electrophoresis on an SDS-PAGE gel. Coomassie stain was used to visualize the protein
in the SDS-PAGE gel.
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Determine the region(s) of N IPB L that interacts with the M L L repression domain
We hypothesized that the region identified in the yeast two-hybrid screen (NIPBL
450-637) would interact with the MLL repression domain. We also thought it was
possible that other regions of NIPBL could interact with the repression domain of MLL.
All of the NIPBL peptides have been expressed and their expression detected
through western blot or immunoprecipitation experiments. To determine the regions of
NIPBL that interact with the MLL repression domain, GST pull-downs were used. The
whole cell lysates containing the FLAG-tagged NIPBL proteins were mixed with GSTtagged MLL RD or GST alone and allowed to bind overnight. If an interaction between
the repression domain of MLL and a subdomain of NIPBL occurred, the GST-tagged
protein bound to beads would pull down any interacting proteins. The resulting mixture
was thoroughly washed and electrophoresed on an SDS-PAGE gel, transferred to PVDF
membrane, and probed with anti-FLAG primary antibody to allow for visualization of the
FLAG-tagged NIPBL constructs. The GST-alone beads were used as a control in each
experiment.
The GST pull-down assays showed that, in fact, the NIPBL 450-637 region does
interact with the repression domain of MLL (Figure 10). As previously mentioned,
NIPBL 450-637 shows multiple bands when run on a SDS-PAGE gel. The lowest band
is believed to be a degradation product within the cells. As seen from the GST pull-down
assays, the degraded product does not interact with the MLL repression domain, while
the upper two bands do (Figure 10). The interaction was demonstrated in five, separate
GST pull-down assays (Figures 10 and A1-4). Untransfected HEK 293T whole cell
lysate was used as negative control. The negative control did not bind to the MLL

39
repression domain or to the GST-alone beads. To serve as a positive control, HDAC1, a
histone deacetylase, which our lab has previously shown to interact with MLL via its
repression domain, was used11. As seen in Figure 10, we confirmed that HDAC1 is able
to interact with the repression domain.
The NIPBL subdomain 590-800, which also expressed well, did not show an
interaction with the MLL repression domain (Figure 11). This experiment was repeated
twice. NIPBL 418-462, the glutamine-rich region, was not pulled-down with the
repression domain of MLL in two separate experiments. GST pull-downs of the
remaining four constructs were each performed once, but no interactions were seen.
Once the expression of the remaining four constructs has been optimized, future GST
pull-down assays will be performed.
From these experiments, we can conclude that the repression domain of MLL
(amino acids 1100-1400) interacts with the Nipped B-like subclone 450-637 as proposed
from the yeast two-hybrid screening results.
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F igure 10: GST Pull-down Assay of M L L R D and N IPB L 450-637

GST pull-down assay. pFLAG-CMV2 NIPBL 450-637 HEK 293T cell lysate was
incubated with GST MLL RD or GST alone. The mixtures were subjected to GST pulldown assay, then electrophoresed on SDS-PAGE (right side). Whole cell lysates of
untransfected HEK 293T cells or of HEK 293T cells transfected with FLAG-tagged
NIPBL or with FLAG-tagged HDAC1 expression plasmids showed input amounts of
proteins (left side of figure). HDAC1, which is known to interact with MLL RD, was the
positive control. Input lanes contained 2%, 5%, and 5%, respectively, of the amount of
cell lysate used in the pull-down experiment. After transfer, the membrane was probed
with anti-FLAG M2 antibody to detect the FLAG-tagged NIPBL and the FLAG-tagged
HDAC1 proteins.
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F igure 11: GST Pull-down Assay of M L L R D and N IPB L 590-800

GST pull-down assay. pFLAG-CMV2 NIPBL 590-800 HEK 293T cell lysate was
incubated with GST MLL RD or GST alone. The mixtures were subjected to GST pulldown assay, then electrophoresed on SDS-PAGE (right side). Whole cell lysates of
untransfected HEK 293T cells or of HEK 293T cells transfected with FLAG-tagged
NIPBL showed input amounts of proteins (left side of figure). Input lanes contained 5%
for each construct of the amount of cell lysate used in the pull-down experiment. After
transfer, the membrane was probed with anti-FLAG M2 antibody to detect the FLAGtagged NIPBL.

CHAPTER FOUR
DISCUSSION
The Mixed Lineage Leukemia ( MLL ) gene was first identified due to its
involvement in chromosomal translocations that can lead to acute myeloid and lymphoid
leukemias1. These MLL leukemias account for nearly ten percent of human acute
leukemias and often present more aggressively and with worse prognoses than other
leukemias3-6.
MLL is a large, multi-domain protein7. The wild type MLL protein contains
several functional domains within the carboxyl terminus of the protein. However, in all
translocations, only the amino-terminus of MLL is fused in-frame to a partner gene. This
results in the formation of a chimeric protein, with the N-terminus intact. Within the Nterminus are three AT-hooks as well as the repression domain10. The repression domain
is present in both wild type and MLL fusion proteins (Figure 1), and functions in both
protein-protein interactions and protein-DNA interactions via the included CXXC
domain11. The repression domain has been shown to bind with histone deacetylases
(HDAC1) and recruit polycomb group proteins, including BMI1 and HPC2. The
repression domain has also been shown to interact with the co-repressor protein, CtBP.
In addition, previous studies in our lab have illustrated that the CXXC/repression domain
of MLL is important in the wild type and leukemic MLL proteins function16,17. There
may still be
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additional, functionally important protein-protein interactions with MLL that have yet to
be determined.
In a recent yeast two-hybrid screen initiated by our lab, the MLL repression
domain (residues 1101-1433) was used as bait to determine interactions with other
proteins in an unbiased manner. This technique is used to identify novel protein-protein
interactions within a yeast system. It was shown that the MLL repression domain
interacts with Nipped B-like protein. With the large number of positive interacting
clones, the interaction of MLL repression domain and Nipped B-like protein was chosen
to validate in another system²GST pull-down from in vitro cultured human cell extracts.
The Nipped B-like protein is part of the cohesin-loading complex, which has been
shown to be important in the cellular processes of mitosis, meiosis, and DNA repair25.
Recent studies have shown that Nipped B-like and the cohesin complex are implicated in
regulating gene expression39-41. Analyses have been performed on Nipped B-like protein
function since the heterozygous loss-of-function mutation that causes Cornelia de Lange
syndrome in humans was uncovered36,38.
Our objective for this thesis was to experimentally confirm the novel interaction
identified between the repression domain of MLL and the Nipped B-like protein. We
hypothesized that the two proteins do interact as shown in the yeast two-hybrid screen.
To validate the interaction, we used the biochemical technique, GST pull-down. This
technique is often used to confirm interactions between two, independent proteins. In our
experiments, we used GST fusion MLL repression domain to pull-down the FLAGtagged Nipped B-like proteins. This combination allowed us to pull-down the proteins of
interest and then blot for those same proteins using the same antibody for detection of
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each NIPBL protein subdomain. Several steps had to first be completed before the
interaction could be tested.
From our western blot and immunoprecipitation experiments, all seven subcloned
regions were expressed²some better than others. NIPBL regions 450-637, 590-800, and
800-1700 were all expressed at an easily detected level with both techniques in multiple
experiments. The remaining four constructs (NIPBL 1-450, 418-462, 1700-2400, and
2400-2597) are shown in one western blot with background, and thus, will need to be
optimized in future experiments. None of these four constructs were detected after
FLAG-immunoprecipitation, which would suggest transfection efficiency and protein
stability as points of future technical optimization.
The full-length Nipped B-like protein, as previously mentioned, is quite large and
was only observed in one western blot. When a GST pull-down assay was performed
with the full length NIPBL, no interaction was seen. This was one reason for analysis of
interaction with the subdomain regions. The subclones allowed for protein expression in
higher amounts that could be used to perform multiple GST pull-down assays. In this
thesis, NIPBL 450-637, NIPBL 418-462, and NIPBL 590-800 were the three subdomain
constructs used in these pull-down experiments. In our experiments, NIPBL 418-462 and
590-800 failed to show an interaction in two independent experiments. However, the
NIPBL subdomain region 450-637, which was the region identified to interact with the
repression domain of MLL through the yeast two-hybrid screen, was shown to interact
with the MLL repression domain in five, separate experiments.
In summary, we have successfully expressed full-length Nipped B-like protein.
In addition, seven domains of Nipped B-like were also cloned and expressed. These
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constructs were used to confirm an interaction between the repression domain of MLL
and Nipped B-like protein as proposed from the results of the previous yeast two-hybrid
screen. The interaction was shown using GST pull-down assays. The repression domain
of MLL (amino acids 1100-1400) was shown to interact with Nipped B-like (450-637).
Confirmation of this novel interaction is only a stepping-stone for future research on
these two important proteins.
The results from this thesis present several possibilities for further investigations.
Immediate experiments to perform hereafter include more experiments on the expression
of the Nipped B-like protein and its subdomains. This thesis included expression of all
seven subclones and the full-length NIPBL proteins; however, difficulties were sustained
with transfection efficiency and antibody optimization. To address these problems,
varying conditions of transient transfection, including amount of DNA with the calcium
phosphate transfection method, or using different methods such as lipid-based
lipofectamine may increase the amount of plasmid DNA taken into the cells. Altering the
method used to solubilize and extract proteins from the cells, as well as conditions used
for immunoprecipiation are possible. We have also obtained a new antibody, which were
used in later experiments and gave less non-specific background on the blots. Using this
better antibody along with optimized secondary antibody and washing conditions may
improve the experiments as well.
It still remains to be determined if the full-length Nipped B-like interacts with the
MLL repression domain, and how they interact. This can be established through
additional protein work. To determine if the full-length Nipped B-like interacts with the
repression domain of MLL, GST pull-down assays would be used again once the full-
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length Nipped B-like was efficiently being expressed and solubilized in HEK 293T cells.
Since we confirmed NIPBL 450-637 to interact with MLL repression domain, we would
expect the full-length protein to interact as well. To deduce whether other regions of
NIPBL can interact with the MLL repression domain, additional GST pull-down assays
would be performed²again, with sufficient protein from new transfections. If other,
separate regions of Nipped B-like appear to interact with the repression domain, we
would have some insight as to how Nipped B-like is folding with regards to its
interaction with MLL. However, if NIPBL 450-637 is the only region to be shown to
interact with the MLL repression domain, the results of this thesis have already begun to
determine Nipped B-OLNH¶VPLQLPDOLQWHUDFWLQJGRPain with the repression domain. As
seen in Figure 10, the two slower migrating bands of NIPBL 450-637 interact with the
MLL RD, while the lower, possibly degraded product does not. We state that the lower
band must contain the N-terminal FLAG-tag as it is detected by anti-FLAG antibody
immunoblot. Since it migrated farther in the SDS-PAGE gel, this band must be lower
molecular weight than the two upper bands. We would predict that the MLL-interacting
region of NIPBL is the carboxy-terminal region of this construct. From NIPBL 450-637,
we could therefore make smaller subdomain regions and perform similar GST pull-down
assays with MLL RD 1100-1400 to determine the minimal amino acid residues that are
required for the interaction.
On the other side of the interaction, the MLL repression domain used in the yeast
two-hybrid screen was amino acids 1101-1433, whereas the GST-tagged MLL repression
domain used for pull-down experiments contained amino acids 1100-1400. We were
therefore able to both confirm the interaction with MLL and determine that amino acids
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1100-1400 were sufficient to mediate interaction with NIPBL. It is still not clear from
the experiments performed which region(s) within the MLL repression domain are
critical to mediate the NIPBL interaction. Within the repression domain is the important
DNA-binding CXXC domain. To identify the minimal NIPBL-interacting domain of
MLL repression domain, smaller constructs of the region could be cloned and expressed.
Similar GST-tagged proteins would be created and bound to glutathione beads so that the
pull-down experiments to determine the minimal MLL interaction domain could be
pursued. It will be important to determine minimal interaction domains from both
NIPBL and MLL in order for structural determination of the interaction by NMR
spectroscopy to be pursued. That would be the next step toward identification of small
molecules, which could inhibit the interaction and could possibly serve as novel
therapeutics.
In addition, it should be noted that the results of the yeast two-hybrid screen and
the GST pull-down assays with whole cell lysates, cannot confirm if this interaction is
direct or indirect in nature. In both systems, additional proteins besides Nipped B-like
and the MLL repression domain could help mediate the interaction. As previously stated,
the MLL repression domain can interact with other proteins, and Nipped B-like could
interact with other proteins through its HEAT repeats, Caldesmon domain, or glutaminerich region. These subsequent proteins could be needed for proper folding and
organization of Nipped B-like and MLL into a larger, multi-subunit protein complex. To
confirm a direct interaction, purified proteins would have to be used to repeat the GST
pull-down assay. To shed light on an indirect interaction through a larger complex,
whole cell immunoprecipitations could be performed to determine whether other proteins
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are pulled-down with either MLL or Nipped B-like. The identity of additional proteins
could be determined by mass spectroscopy. These interaction studies would give the
needed basis for future studies that look at the expanding role of Nipped B-like and
cohesin as transcriptional regulators. As previously stated, MLL is a positive regulator of
genes in embryonic and hematopoietic development. Cohesin and Nipped B-like have
been linked to both positive and negative regulation of various gene loci39-41. This thesis
and future protein interaction studies would be the foundation of placing these two
proteins at the same point within a cell.
To begin to elucidate functional roles of these two proteins within the cell, several
experimental techniques could be used. First, ChIP and ChIP-seq could be used to
determine if MLL and Nipped B-like are binding to the same genes, where they are
binding to these genes, and if they are binding at different times. Both abovementioned
techniques have been shown before for MLL and Nipped B-like separately, and using
different cell types, but we would like to confirm that both MLL and Nipped B-like are
located at the same genes simultaneously in the same cell type. If this experiment was
performed, we would hope, based on the interaction results of this thesis, that both MLL
and Nipped B-like would be positioned at the same genes as depicted in our model
(Figure 12). Having the two proteins at the same genes would allow further analysis into
the regulation and expression of the gene targets of MLL and Nipped B-like.
As noted previously, MLL fusion proteins cause both acute myeloid and
lymphoid leukemias in humans whereas mutations in Nipped B-like lead to Cornelia de
Lange syndrome (CdLS). Leukemias and CdLS show their effects in the early,
GHYHORSPHQWDOVWDJHVRIOLIHDQGWKHUHIRUHOLPLWRQH¶V\HDUV2XUXOWLPDWHIRFXVRI
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future studies would be to gain information on how the two proteins, MLL and Nipped Blike, affect these two medical conditions in order to effectively treat future patients.
Some of the known gene targets of MLL and MLL fusion protein function are the HOX
genes, which are critical in development. It would be especially important to determine
whether MLL and NIPBL co-regulated expression of HOX genes is crucial for both
normal hematopoiesis as well as developmental pathways altered in CdLS.
In CdLS, we would like to ask if MLL is required to still see the same
developmental abnormalities and effects of the syndrome. To do this, we would use
MLL null (-/-) cells as the basis for ChIP studies. Any changes in gene regulation of
genes related to CdLS in the null cells, as compared to wild type MLL, would be genes of
interest.
For MLL leukemias, we could see if Nipped B-like heterozygosity (+/-), which
causes CdLS, could be an effective therapeutic for inhibiting the transformational
capacity of MLL fusion cells. In this experiment, we would transfect NIPBL +/- cells
with a MLL fusion plasmid²to produce the MLL fusion protein within the CdLS
environment. From here, we would determine if the transfected cells were able to
transform (i.e. confer leukemia) or not. If the cells were unable to transform based on the
NIPBL +/-, this could lead to insight of the fact that Nipped B-like and cohesin¶VHIIHFWV
on gene regulation also have an effect on the MLL IXVLRQ¶VDELOLW\WRFDXVHOHXNHPLD
Put together, if these results were seen, Nipped B-like could be a possible therapeutic for
targeting MLL leukemias.
As seen in prior studies, chromosome conformation capture (3C) can be used to
determine if there is DNA looping at genes. In our case, the previously mentioned
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combinations of cell lines (MLL-/- and NIPBL +/-) would be used to determine looping
at MLL- and Nipped B-like-specific genes. 3C would allow us to confirm DNA looping,
such as between gene enhancers and promoters, and ChIP-seq would allow us to
immunoprecipitate for proteins at the bases of the loops. From the thesis data, we would
hypothesize to see both MLL and Nipped B-like at the bases of the looping regions
(Figure 12) in wild type and MLL fusion cells leading to transcriptional upregulation.
However, a decrease of recruitment would be noted in cells with decreased Nipped B-like
(NIPBL +/-) levels, which mimic the effects of CdLS. Finally, the MLL -/- cells would
show if MLL is required for Nipped B-like to be engaged at MLL-specific genes.
The combined data from this thesis and future research is what I hope to be used
in accomplishing significant strides in the understanding how both the MLL leukemias
and Cornelia de Lange Syndrome are caused by these proteins of interest, and potential
points for therapeutic intervention.
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F igure 12: Nipped B-like interaction with the M L L Repression Domain

Schematic model depicting the potential functional outcome of an interaction between
Nipped B-like and the MLL repression domain. An interaction between NIPBL and
MLL could lead to the possibility of positive regulation of MLL target genes within the
cell. For this to occur, NIPBL, with MLL bound, would loop DNA and allow for
recruitment of the Mediator complex and RNA polymerase to transcribe the genes.

APPENDIX A
SUPPLEMENTAL DATA

[52]

[53]
F igure A1: GST Pull-down Assay of M L L R D and Nipped B-like

GST pull-down assay. pFLAG-CMV2 NIPBL 450-637 HEK 293T cell lysate was
incubated with GST MLL RD or GST alone. The mixtures were subjected to GST pulldown assay. Whole cell lysates were immunoblotted and probed with anti-FLAG M2 to
detect the FLAG-tagged NIPBL protein. Untransfected HEK 293T whole cell lysate
served as a negative control. Input lanes were 2% and 5%, respectively.

[54]
F igure A2: GST Pull-down Assay of M L L R D and Nipped B-like

GST pull-down assay. pFLAG-CMV2 NIPBL 450-637 HEK 293T cell lysate was
incubated with GST MLL RD or GST alone. The mixtures were subjected to GST pulldown assay. Whole cell lysates were immunoblotted and probed with anti-FLAG M2 to
detect the FLAG-tagged NIPBL protein. Untransfected HEK 293T whole cell lysate
served as a negative control. Input lanes were 2% and 5%, respectively.

[55]
F igure A3: GST Pull-down Assay of M L L R D and Nipped B-like

GST pull-down assay. pFLAG-CMV2 NIPBL 450-637 HEK 293T cell lysate was
incubated with GST MLL RD or GST alone. The mixtures were subjected to GST pulldown assay. Whole cell lysates were immunoblotted and probed with anti-FLAG M2 to
detect the FLAG-tagged NIPBL protein. Untransfected HEK 293T whole cell lysate
served as a negative control. Input lanes were 2% and 5%, respectively.

[56]
F igure A4: GST Pull-down Assay of M L L R D and Nipped B-like

GST pull-down assay. pFLAG-CMV2 NIPBL 450-637 HEK 293T cell lysate was
incubated with GST MLL RD or GST alone. The mixtures were subjected to GST pulldown assay. Whole cell lysates were immunoblotted and probed with anti-FLAG M2 to
detect the FLAG-tagged NIPBL protein. Untransfected HEK 293T whole cell lysate
served as a negative control. Input lanes were 2% and 5%, respectively.
NIPBL 450-637 is boxed in red.

[57]
F igure A5: Sequencing V erification of N IPB L 1-450
>A1_CMV30 sequence exported from A1_CMV30.ab1
AATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCG
TCAGCAATTGATCTACCATGGACTACAAAGACGATGACGACAAGCTTGCGGCCGCGAATT
CATCGATAGATCTGATATCGGTACCAG T C G A CATGAATGGGGATATGCCCCATGTCCCCA
TTACTACTCTTGCGGGGATTGCTAGTCTCACAGACCTCCTGAACCAGCTGCCTCTTCCAT
CTCCTTTACCTGCTACAACTACAAAGAGCCTTCTCTTTAATGCACGAATAGCAGAAGAGG
TGAACTGCCTTTTGGCTTGTAGGGATGACAATTTGGTTTCACAGCTTGTCCATAGCCTCA
ACCAGGTATCAACAGATCACATAGAGTTGAAAGATAACCTTGGCAGTGATGACCCAGAAG
GTGACATACCAGTCTTGTTGCAGGCCGTCCTGGCAAGGAGTCCTAATGTTTTCAGGGAGA
AAAGCATGCAGAACAGATATGTACAAAGTGGAATGATGATGTCTCAGTATAAACTTTCTC
AGAATTCCATGCACAGTAGTCCTGCATCTTCCAATTATCAACAAACCACTATCTCACATA
GCCCCTCCAGCCGGTTTGTGCCACCACAGACAAGCTCTGGGAACAGATTTATGCCACAGC
AAAATAGCCCAGTGCCTAGTCCATACGCCCCACAAAGCCCTGCAGGATACATGCCATATT
CCCATCCTTCAAGTTACACAACACATCCACAGATGCAACAAGCATCGGTATCAAGTCCCA
TTGTTGCAGGTGGTTTGAGAAACATACATGATAATAAAGTTTCTGGTCCGTTGTCTGGCA
ATTCAGCTAATCATCATGCTGATAATCCTAGACATGGTTCAAGTGAGGACTACCTACACA
TGGTGCACAGGCTAAGTAGTGACGATGGAGATTCTTCAACAATGAGGAATGCTGCATCTT
TTCCCTTGAGATCTCCACAGCCAGTATGCTCCCCTGCTGGAAGTGAAGGAACTCCTAAAG
GC

>A1_CMV24 sequence exported from A1_CMV24.ab1
GAGCCGGAATTTATCCCCCCAGCAGAAATAGCACCAAGGACTAGGTCCCGTAGGGCCCCC
AACAAAAGGCGTGCAGGGATGACAATACCATTATTCCCCATCCCTTCCAGTTTACACAAA
CACATCCCAGGGATGCACCAAGGCATCGGATATTCAAGTCCCCATTGTAGCAAGGGGGTT
TGAGGAAACATACATGATAATAAAAGTTTCTGGTCCCGTTGTCTGGCAATTCAGCTAATC
ATCATGTTGATAATCCTAGACATGGTTCAAGTGAGGACTACCTACACATGGTGCACAGGC
TAAGTAGTGACGATGGAGATTCTTCAACAATGAGGAATGCTGCATCTTTTCCCTTGAGAT
CTCCACAGCCAGTATGCTCCCCTGCTGGAAGTGAAGGAACTCCTAAAGGCTCAAGACCAC
CTTTAATCCTACAATCTCAGTCTCTACCTTGTTCATCACCTCGAGATGTTCCACCAGATA
TCTTGCTAGATTCTCCAGAAAGAAAACAAAAGAAGCAGAAGAAAATGAAATTAGGCAAGG
ATGAAAAAGAGCAGAGTGAGAAAGCGGCAATGTATGATATAATTAGTTCTCCATCCAAGG
ACTCTACTAAACTTACATTAAGACTTTCTCGTGTAAGGTCTTCAGACATGGACCAGCAAG
AGGATATGATTTCTGGTGTGGAAAATAGCAATGTTTCAGAAAATGATATTCCTTTTAATG
TGCAGTACCCAGGACAGACTTCAAAAACACCCATTACTCCACAAGATATAAACCGCCCAC
TAAATGCTGCCCAATGTTTGTCGCAGCAAGAACAAACAGCATTCCTTCCAGCAAATCAAG
TGCCTGTTTTACAACAGAACACTTCAGTTGCTGCAAAACAACCCCAGAGTTCTGTGTGAG
G A T C CCGGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTGCTGGGCTGAACTAGGGCA
CACTACATACTAGAAGCG

In the above figure, restriction enzyme sites are displayed as bolded text. The stop codon
is highlighted in red, and the pFLAG-CMV2 expression vector sequence is labeled in
blue. The plain, capitalized text is the coding sequence of Nipped B-like.

[58]
F igure A6: Sequencing V erification of N IPB L 418-462
>G5_CMV30 sequence exported from G5_CMV30.ab1
CAAAATTGGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTG
AACCGTCAGAATTGATCTACCATGGACTACAAAGACGATGACGACAAGCTTGCGGCCGC G
A A T T CTCAATGTTTGTCGCAGCAAGAACAAACAGCATTCCTTCCAGCAAATCAAGTGCCT
GTTTTACAACAGAACACTTCAGTTGCTGCAAAACAACCCCAGACTTCTGTGGTACAGAAT
CAACAACAGATATCACAACAGTGAG G A T C CCGGGTGGCATCCCTGTGACCCCTCCCCAGT
GCCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATT
AAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGT
GGTATGGACCACTGACCAATTATTAATGATAACCTCCAGGGTAGTCAATACTCAAGAAAG
CATAGTACTAGTGACCTGTCCTCATAATTGACTCAAAGCAACCCCCGGATAAAGGGTAAG
CAACGCCCAACCGTTTACGTTAAGCGGTATGTTCGCTTTCAAAGTATGTTCAGGACTTAT
TTCGATTTTGGTGAATTGTTGGTATAATTAGCGCTGATCGCCCATATGTAAGTCAGCCCC
ATGACTTCTAAGCTGACTCGAAAGCCTCGTGACGGGCTTGTCAGTTGCCGT

In the above figure, restriction enzyme sites are displayed as bolded text. The stop codon
is highlighted in red, and the pFLAG-CMV2 expression vector sequence is labeled in
blue. The plain, capitalized text is the coding sequence of Nipped B-like.

[59]
F igure A7: Sequencing V erification of N IPB L 450-637
>F1_CMV30 sequence exported from F1_CMV30.ab1
AATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCG
TCAGAATTGATCTACCATGGACTACAAAGACGATGACGACAAGCTTGCGGCCGC G A A T T C
TGTGGTACAGAATCAACAACAGATATCACAACAGGGACCTATATATGATGAAGTGGAATT
GGATGCATTGGCTGAAATTGAGCGAATAGAGAGAGAATCAGCTATTGAAAGGGAGCGCTT
CTCAAAAGAAGTTCAAGATAAAGATAAGCCTTTGAAAAAAAGAAAACAAGATTCTTACCC
ACAGGAGGCTGGGGGTGCTACAGGAGGTAATAGACCAGCTTCTCAGGAGACGGGTTCTAC
GGGAAATGGGTCAAGGCCAGCATTAATGGTTAGCATTGATCTTCATCAGGCAGGAAGAGT
GGACTCTCAGGCTTCTATAACTCAGGATTCAGACTCCATAAAAAAGCCTGAAGAAATCAA
ACAATGTAATGATGCACCTGTTTCTGTTCTTCAGGAAGATATTGTTGGAAGTCTTAAATC
TACACCAGAAAACCATCCTGAGACACCTAAAAAAAAGTCTGATCCTGAGCTTTCAAAGAG
TGAAATGAAACAAAGTGAAAGTAGATTAGCAGAATCTAAACCAAATGAAAACCGATTGGT
GGAGACAAAATCAAGTGAATGAG G A T C CCGGGTGGCATCCCTGTGACCCCTCCCCAGTGC
CTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTAA
GTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAAGGGGGGGT
GG

In the above figure, restriction enzyme sites are displayed as bolded text. The stop codon
is highlighted in red, and the pFLAG-CMV2 expression vector sequence is labeled in
blue. The plain, capitalized text is the coding sequence of Nipped B-like.

[60]
F igure A8: Sequencing V erification of N IPB L 590-800
>B6_CMV30 sequence exported from B6_CMV30.ab1
AACTGGACGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACC
GTCAGAATTGATCTACCATGGACTACAAAGACGATGACGACAAGCTTGCGGCCGC G A A T T
CTAAATCTACACCAGAAAACCATCCTGAGACACCTAAAAAAAAGTCTGATCCTGAGCTTT
CAAAGAGTGAAATGAAACAAAGTGAAAGTAGATTAGCAGAATCTAAACCAAATGAAAACC
GATTGGTGGAGACAAAATCAAGTGAAAATAAGTTAGAAACTAAAGTTGAGACCCAAACAG
AAGAACTTAAACAGAATGAGAGCAGAACAACTGAATGCAAACAAAACGAGAGCACCATAG
TTGAGCCTAAACAAAATGAAAATAGACTGTCTGACACAAAACCAAATGACAACAAACAAA
ATAATGGCAGATCAGAAACAACAAAATCAAGGCCTGAAACCCCAAAGCAAAAGGGTGAAA
GCCGGCCTGAGACTCCAAAACAAAAGAGTGATGGGCATCCTGAAACCCCAAAACAGAAGG
GTGATGGAAGGCCTGAAACTCCAAAGCAAAAAGGTGAGAGCCGCCCTGAAACTCCAAAGC
AAAAAAATGAAGGGCGACCTGAAACACCAAAACACAGGCATGACAATAGGAGGGATTCTG
GAAAGCCATCTACAGAGAAAAAACCTGAAGTGTCTAAACATAAACAAGATACTAAATCTG
ACTCACCTCGGTTAAAATCAGAACGAGCTGAAGCCTGAG G A T C CCGGGTGGCATCCCTGT
GACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTT
GTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATG
GGGTGGGAGGGGGGGGTG

In the above figure, restriction enzyme sites are displayed as bolded text. The stop codon
is highlighted in red, and the pFLAG-CMV2 expression vector sequence is labeled in
blue. The plain, capitalized text is the coding sequence of Nipped B-like.

[61]
F igure A9: Sequencing V erification of N IPB L 800-1700
>C8_CMV30 sequence exported from C8_CMV30.ab1
AAGCGGAAAGGACGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGT
GAACCGTCAGAATTGATCTACCATGGACTACAAAGACGATGACGACAAGCTTGCGGCCGC
G A A T T CAGCCTTAAAGCAGAGACCTGATGGGCGATCTGTTTCTGAGTCACTAAGACGTGA
CCATGATAATAAACAAAAATCAGATGACAGGGGTGAATCAGAGCGACATCGAGGGGATCA
GTCTAGGGTTCGAAGACCAGAAACATTGAGATCCTCTAGTAGAAATGAACATGGCATTAA
ATCTGATAGTTCAAAAACTGATAAACTAGAACGAAAACACAGGCATGAATCAGGGGACTC
AAGGGAAAGACCATCTTCTGGGGAACAAAAATCAAGACCTGACAGTCCTCGTGTTAAACA
AGGAGATTCTAATAAATCAAGATCTGATAAACTTGGTTTTAAATCACCAACTAGTAAAGA
TGACAAAAGGACAGAGGGTAACAAGAGTAAAGTAGACACTAATAAAGCACACCCTGACAA
TAAGGCAGAATTTCCAAGTTATTTGTTGGGGGGCAGGTCTGGTGCGTTGAAAAATTTTGT
CATTCCGAAAATCAAGAGGGATAAAGATGGCAATGTTACTCAGGAGACAAAGAAAATGGA
AATGAAAGGAGAGCCGAAAGACAAAGTAGAAAAAATAGGATTAGTTGAAGATCTAAATAA
AAGGAGCTAAAGCCTGTAGTTGTGCTACAAAAACTGTCTTTGGATGATGTTCAGAAACTT
TATTTAAAGATAGAGAGGACAAAATCAAAGAAAGTTCCCTTAAACCCTATCAAAGAATAA
AACCCATCTAAAAGTCAAAATAAAAGGTAGTATAAGATCAATCAGGTGTTTAAAAAGAAA
TTACCCCCCCTGGAAACTTCCTTGGCCAGAAAATTTGAGTCCCACCCATGGGCCAACTTT
TTGGTGAAACCGTGGTGGAAAAATTGGAAACTAA

>C8_NIP-C-R sequence exported from C8_NIP-C-R.ab1
GTAGTATAGATCAATCAGTGTTAAAAGAATTACCCCCTGAACTCCTGGCAGAAATTGAGT
CCACCATGCCACTTTGTGAACGTGTGAAAATGAACAAACGCAAGCGTAGCACAGTTAATG
AAAAGCCAAAATATGCTGAAATCAGTTCAGATGAAGATAATGATAGTGATGAAGCTTTTG
AATCCTCTAGGAAACGACATAAAAAAGATGATGATAAAGCTTGGGAATATGAAGAGCGTG
ACAGAAGAAGCTCTGGGGATCATAGGAGAAGTGGCCACTCTCATGAAGGAAGAAGGAGTT
CAGGTGGTGGTCGTTATCGAAACCGAAGTCCGTCAGATTCTGACATGGAAGATTATTCTC
CTCCTCCCAGCCTTAGTGAGGTTGCTAGGAAAATGAAGAAAAAAGAAAAACAGAAGAAAA
GGAAAGCATATGAACCAAAACTAACACCTGAAGAAATGATGGACTCTTCAACTTTTAAGA
GATTCACAGCCTCAATAGAGAATATTTTGGATAATTTGGAAGATATGGATTTTACTGCGT
TTGGTGATGATGATGAAATTCCTCAGGAACTGCTCTTAGGAAAACATCAGCTTAATGAAC
TTGGCAGTGAATCTGCTAAAATAAAAGCAATGGGTATAATGGATAAGCTTTCAACTGACA
AAACTGTGAAAGTCTTAAATATCTTGGAGAAGAATATTCAGGATGGGTCAAAGCTTTCCA
CTTTGTTAAATCATAATAACGATACTGAAGAAGAAGAAAGGTTATGGAGAGACCTTATTA
TGGAGAGAGTTACAAAATCAGCGGATGCTTGTCTTACAACTATCAACATTATGACATCCC
CTAACATGCCAAAAGCTGTGTACATTGAGGATGTAATTGAAAGAGTTATACAGTACACTA
AATTTCATTTGCAGAATACACTTTATCCTCAGTATGATCCTGTTTACAGATTAGATCCTC
ATGGAGGAGGCTTATTAAGTTCAAAAGCAAAACGGGCTAAATGTTCTACCCATAAGCAGA
GAGTAATAGTAATGCTTTAGCAGT

>C8_CMV24 sequence exported from C8_CMV24.ab1
CGGGCTAAATGTTCTACCCATAAGCAGAGAGTAATAGTAATGCTTTATAACAAAGTTTGT
GACATTGTTAGCAGCTTATCAGAATTGCTAGAGATACAACTTCTTACAGACACAACAATT
CTTCAGGTTTCATCTATGGGAATAACACCATTTTTTGTGGAAAATGTCAGTGAACTACAG
TTGTGTGCCATTAAGTTAGTCACTGCAGTATTCTCAAGATATGAAAAACATAGGCAGTTA
ATTTTGGAAGAAATTTTTACTTCACTTGCAAGATTACCAACCAGCAAGAGGAGTTTAAGG
AACTTCAGGTTAAACAGTAGTGATATGGATGGAGAACCTATGTATATTCAGATGGTTACA
GCACTGGTTTTACAACTTATTCAGTGTGTGGTACACTTACCATCATCAGAGAAGGACTCT
AATGCAGAAGAAGATTCAAATAAAAAAATTGACCAGGATGTTGTCATTACTAACTCTTAT
GAAACAGCTATGCGAACAGCCCAAAACTTCCTCTCCATCTTCCTTAAAAAATGTGGTAGT
AAGCAAGGTGAAGAAGATTACAGACCACTGTTTGAAAATTTTGTTCAAGACCTTCTTTCA
ACAGTCAATAAGCCTGAATGGCCAGCTGCTGAACTACTCCTTAGTTTGTTAGGGAGACTG
TTGGTTCATCAGTTCAGTAACAAGTCAACAGAGATGGCTTTAAGAGTGGCATCTCTTGAT
TACCTTGGAACTGTTGCTGCACGGCTAAGAAAAGATGCTGTTACAAGCAAAATGGATCAA

[62]
GGATCTATAGAACGCATTTTAAAACAGGTTTCAGGAGGGGAAGATGAAATCCAACAATTA
CAAAAAGCATTGCTTGATTACTTGGATGAAAACACTGAGACTGATCCTTCACTAGTGTTT
TCTCGTAAATTCTATATAGCCCAGTGGTTTCGAGACACAACTCTGGAAACAGAAAAAGCA
ATGAAATCACAAAAAGATGAAGAATCATCTTGAG G A T C C CGGGTGGCATCCCTGTGACCC
CTCCCCAGTGCCTTCCTGGCCTGAAGTGCTGACCC

In the above figure, restriction enzyme sites are displayed as bolded text. The stop codon
is highlighted in red, and the pFLAG-CMV2 expression vector sequence is labeled in
blue. The plain, capitalized text is the coding sequence of Nipped B-like.

[63]
F igure A10: Sequencing V erification of N IPB L 1700-2400
>D2_CMV30 sequence exported from D2_CMV30.ab1
AACTTGGAGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAA
CCGTCAGACTTGATCTACCATGGACTACAAAGACGATGACGACAAGCTTGCGGCCGCGAA
TTCATCGATAGATCT G A T A T CATCTGAAGGAACACATCATGCAAAGGAAATTGAGACAAC
TGGCCAAATTATGCATCGAGCTGAAAACCGAAAAAAGTTTCTTAGAAGCATTATCAAAAC
CACACCTTCTCAGTTTAGCACATTAAAGATGAACTCTGATACTGTGGACTATGATGATGC
TTGCTTGATTGTTCGATACTTGGCCTCCATGAGGCCGTTTGCCCAGAGCTTTGATATTTA
TTTGACACAGATCCTACGAGTTCTTGGTGAAAATGCAATTGCTGTTCGAACAAAAGCCAT
GAAGTGTTTGTCTGAGGTTGTTGCTGTAGACCCCAGTATTCTAGCAAGGCTTGATATGCA
ACGAGGTGTTCATGGACGATTGATGGATAATTCGACTAGTGTCCGAGAAGCAGCAGTAGA
ATTACTAGGTCGATTTGTCCTTTGTCGACCTCAGCTTGCTGAACAGTATTATGATATGCT
GATTGAAAGAATATTGGATACTGGTATCAGTGTCAGGAAAAGAGTAATAAAGATTCTCAG
AGACATTTGTATTGAACAACCAACATTTCCAAAAATCACAGAAATGTGTGTAAAAATGAT
TCGCAGAGTCAATGATGAAGAGGGCATTAAGAAATTAGTAAATGAAACATTCCAGAAACT
CTGGTTTACTCCAACTCCACACAATGACAAAGAAGCAATGACAAGGAAAATTTTAAACAT
TACCGATGTGGTTGCAGCATGCAGAGATACTGGATATGACTGGTTTGAGCAACTGCTTCA
AAACTTGTTGAAGTCCGAAGAGGATTCCTCATATAAACCTGTGAAGAAAGCTTGTACTCA
ACTTGTTGATAACCTAGTTGAGCCCATTCTTAAATATGAAGGAATCTCTAGCTGACTCTG
ACAATAAAAGGGGTGAATTT

>D2_CMV24 sequence exported from D2_CMV24.ab1
ATATAATAAAAATAAATATATAGTGGCAGTTTTAAGAATTAAAAAAGTGACGCGCAGAGG
GACCAAAATAAACATTTCATTTTTAACAAACAACCAGCAATTTGTTAGATCCCTTTTTCA
CCGTTGGAGCACTATGTCGGCATTTAAAATTTTGATCTGGAAGATTTTAAAGGCAACAGC
AAGGTTAACATAAAAGATAAAGTACTTGAACTATTGATGTATTTTACAAAACACTCAGAT
GAAGAAGTACAAACAAAAGCTATCATTGGTCTAGGATTTGCCTTTATTCAGCATCCAAGT
CTAATGTTCGAGCAAGAAGTGAAGAATCTATATAATAATATTTTATCTGATAAGAACTCC
TCAGTCAATTTAAAAATACAAGTGTTAAAAAACCTCCAGACCTACCTACAAGAAGAAGAT
ACACGTATGCAGCAGGCAGATAGAGACTGGAAGAAAGTTGCAAAACAGGAAGACTTAAAA
GAAATGGGTGATGTTTCCTCAGGGATGAGTAGTTCCATCATGCAGCTTTATCTCAAACAG
GTGCTTGAGGCATTTTTTCACACCCAGTCAAGTGTACGCCACTTTGCCCTAAATGTCATT
GCATTGACTCTAAATCAAGGTCTTATTCATCCAGTTCAGTGTGTGCCATATTTAATTGCT
ATGGGCACAGACCCAGAACCTGCTATGCGGAACAAGGCTGATCAGCAACTTGTGGAAATA
GACAAAAAATATGCTGGATTCATTCATATGAAAGCAGTGGCTGGTATGAAGATGTCTTAC
CAGGTACAACAGGCAATCAACACATGCCTAAAAGATCCTGTAAGGGGTTTCAGACAAGAC
GAGTCCTCTAGCGCTTTGTGTTCACACCTTTACTCCATGATCCGTGGATGAG G A T C C CGG
GTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCTGAAGGATTCAGGTCGAGCG
CGTAGGTAGAGA

In the above figure, restriction enzyme sites are displayed as bolded text. The stop codon
is highlighted in red, and the pFLAG-CMV2 expression vector sequence is labeled in
blue. The plain, capitalized text is the coding sequence of Nipped B-like.

[64]
F igure A11: Sequencing V erification of N IPB L 2400-2597
>E1_CMV30 sequence exported from E1_CMV30.ab1
AATGGACGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCG
TCAGAATTGATCTACCATGGACTACAAAGACGATGACGACAAGCTTGCGGCCGC G A A T T C
TGGAAACCGCCAACACAGACGAGCCTTTCTTATTTCTTTACTCAACCTCTTTGATGACAC
AGCAAAAACAGACGTGACTATGCTCTTGTATATAGCAGACAATCTAGCCTGTTTTCCATA
CCAGACACAGGAAGAGCCGTTGTTTATAATGCATCATATAGACATTACACTCTCAGTTTC
TGGTAGTAACCTACTGCAGTCATTCAAGGAGTCTATGGTAAAGGACAAAAGGAAAGAGAG
AAAATCATCACCTAGTAAGGAAAATGAGTCAAGCGACAGTGAAGAAGAAGTTTCCAGGCC
TCGGAAGTCACGGAAACGTGTAGATTCAGATTCAGATTCAGATTCAGAAGACGATATAAA
TTCAGTGATGAAATGTTTGCCAGAAAATTCAGCTCCTTTAATCGAATTTGCAAATGTGTC
CCAGGGTATTTTATTACTTCTCATGTTAAAACAACATTTGAAGAATCTTTGTGGATTTTC
TGATAGTAAAATTCAGAAGTACTCTCCATCTGAATCTGCAAAAGTATATGATAAAGCGAT
AAACCGAAAAACAGGAGTTCATTTTCATCCAAAACAAACACTGGACTTCCTGTGAG G A T C
CCGGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTC
CAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGT
CCTTCTATAATATTATGGGGTGGAAGGGGGGGGG

In the above figure, restriction enzyme sites are displayed as bolded text. The stop codon
is highlighted in red, and the pFLAG-CMV2 expression vector sequence is labeled in
blue. The plain, capitalized text is the coding sequence of Nipped B-like.
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